PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 — Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of an every-four-weeks (E4W) dosing regimen for Elfabrio in adult patients with Fabry disease who are stable on enzyme replacement therapy. The opinion, issued following a re-examination, will now be reviewed by the European Commission, with a final decision expected by March 2026.
Science Significance
The CHMP opinion is grounded in robust clinical evidence demonstrating that pegunigalsidase alfa administered at 2 mg/kg every four weeks maintains safety, efficacy, and pharmacokinetic stability comparable to the standard biweekly regimen. Data from the BRIGHT open-label switch-over study and its long-term extension, with a median exposure approaching six years, showed sustained disease control across key Fabry-related parameters. Supported by population pharmacokinetic modeling and exposure–response analyses, the findings confirm that less frequent dosing can preserve therapeutic exposure while reducing treatment intensity. Scientifically, this represents an important advance in enzyme replacement therapy optimization, demonstrating how dosing flexibility can be achieved without compromising clinical outcomes.
Regulatory Significance
From a cGxP perspective, the positive CHMP opinion reflects a successful post-approval lifecycle management strategy for a complex biologic. Approval of an additional dosing regimen requires comprehensive GCP-compliant clinical data, validated modeling, and a rigorous benefit–risk reassessment. The re-examination outcome highlights regulatory confidence in the data integrity, long-term safety monitoring, and manufacturing consistency of Elfabrio. If endorsed by the European Commission, the decision will result in a label update across the EU, reinforcing the importance of continuous evidence generation and regulatory engagement throughout a biologic’s commercial lifecycle.
Business Significance
Advertisement
For Chiesi and Protalix, the positive CHMP opinion represents a strategic value driver for Elfabrio in the competitive rare disease market. An approved monthly dosing option could enhance market differentiation, support broader physician adoption, and improve long-term patient retention. The milestone also carries direct financial implications, as Protalix becomes eligible for a $25 million regulatory milestone payment upon European Commission approval. More broadly, the decision validates Protalix’s ProCellEx® plant cell–based manufacturing platform, underscoring its capability to support globally approved biologics under stringent GMP standards.
Patients’ Significance
For people living with Fabry disease, the potential approval of an every-four-week dosing regimen represents a meaningful reduction in treatment burden. Current biweekly infusions require frequent visits to infusion centers, disrupting work, education, and family life. Extending the interval between infusions can improve quality of life, reduce caregiver strain, and support better long-term adherence. Patient advocacy leaders have emphasized that treatment success is not only about clinical efficacy, but also about therapies that fit into everyday life, making this regulatory step particularly impactful for the Fabry community.
Policy Significance
The CHMP opinion aligns with broader European healthcare policy goals focused on patient-centered care, efficient use of healthcare resources, and sustainable treatment models for rare diseases. Reduced infusion frequency may lower system-wide costs associated with infusion center utilization while maintaining high standards of care. At a policy level, the decision reinforces the EMA’s openness to adaptive treatment strategies supported by strong real-world and long-term clinical evidence, potentially influencing future regulatory approaches to dosing flexibility in chronic biologic therapies.
With the CHMP’s positive opinion, Elfabrio moves closer to offering greater dosing flexibility for adults with Fabry disease across the European Union. Pending European Commission approval, the every-four-weeks regimen would mark a significant advance in biopharma lifecycle innovation, balancing scientific rigor, regulatory compliance, and patient needs. The milestone underscores how GxP-driven evidence generation and collaborative regulatory engagement can translate into tangible improvements for patients living with rare, lifelong conditions.
Source: Chiesi Global Rare Diseases and Protalix BioTherapeutics press release
